Literature DB >> 17940772

Initiating etanercept in a once weekly dose in children with juvenile idiopathic arthritis.

Femke H M Prince, Lisette W A van Suijlekom-Smit.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17940772     DOI: 10.1007/s00296-007-0468-5

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


× No keyword cloud information.
  4 in total

1.  Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.

Authors:  Dong-Seok Yim; Honghui Zhou; Mary Buckwalter; Ivan Nestorov; Carl C Peck; Howard Lee
Journal:  J Clin Pharmacol       Date:  2005-03       Impact factor: 3.126

2.  Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study.

Authors:  Femke H M Prince; Marinka Twilt; Nelleke C J A Jansen-Wijngaarden; Lisette W A van Suijlekom-Smit
Journal:  Ann Rheum Dis       Date:  2007-02-26       Impact factor: 19.103

Review 3.  The German etanercept registry for treatment of juvenile idiopathic arthritis.

Authors:  G Horneff; H Schmeling; T Biedermann; I Foeldvari; G Ganser; H J Girschick; T Hospach; H I Huppertz; R Keitzer; R M Küster; H Michels; D Moebius; B Rogalski; A Thon
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

4.  Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis.

Authors:  Jasmin B Kuemmerle-Deschner; Gerd Horneff
Journal:  Rheumatol Int       Date:  2007-07-20       Impact factor: 2.631

  4 in total
  1 in total

Review 1.  Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.

Authors:  Susan Shenoi; Carol A Wallace
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.